Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 24, 2020 01:00 ET | Source: ORPHAZYME A/S

Orphazyme phase 2 study of arimoclomol in Gaucher disease demonstrates marked improvements in key clinical markers

Orphazyme A/SCompany announcement No. 36/2020 ...
November 27, 2018 08:51 ET | Source: ORPHAZYME A/S

Publication of manuscript on preclinical Proof-of-Concept of arimoclomol in Gaucher disease

Orphazyme A/SInvestor news No....
June 21, 2018 03:17 ET | Source: ORPHAZYME A/S

Enrollment of first patient in Phase II clinical trial for Gaucher disease

Orphazyme A/SCompany announcement No....
February 06, 2018 11:38 ET | Source: ORPHAZYME A/S

Poster presentation at WORLDSymposium™ 2018 – arimoclomol as clinical candidate for treatment of Gaucher disease

Investor newsOrphazyme A/SNo. 02/2018 ...
March 09, 2017 07:30 ET | Source: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics to Hold Full-Year 2016 Financial Results and Corporate Update Conference Call on March 16, 2017

CARMIEL, Israel, March 09, 2017 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of...
December 14, 2016 07:30 ET | Source: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics Receives Letter Detailing Intended Purchases of Approximately $24 Million of alfataliglicerase to Treat Gaucher Patients in Brazil

CARMIEL, Israel, Dec. 14, 2016 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX) (the “Company”) announced today that the Company received a letter from Fundação Oswaldo...